Indian healthtech startup Ultrahuman said it has raised US$70 million in a new funding round led by Qualcomm Ventures, with participation from Labcorp, Alpha Wave, Blume, Nexus, Alteria and others. The company plans to use the capital to scale its AI driven sensing technology, health algorithms and miniaturised electronics, and to expand its metabolic health and research platforms globally.
This article aggregates reporting from 1 news source. The TL;DR is AI-generated from original reporting. Race to AGI's analysis provides editorial context on implications for AGI development.
Ultrahuman’s US$70 million round is another sign that AI‑native hardware at the edge is maturing into a serious business, not just a gadget niche. By combining continuous biosensing, environmental data and an AI layer (Jade) that provides “conversational health intelligence,” Ultrahuman is effectively building a personalised inference engine that runs as close to the body as possible. That is strategically important because whoever owns the continuous data stream on human physiology will have a unique asset for training models that understand and predict health states.
For the broader AGI race, this plays into a trend where leading models are increasingly fine‑tuned on narrow, high‑value domains like medicine, fitness and sleep. A dense, longitudinal dataset from wearables and clinical programs gives Ultrahuman leverage in collaborating with or competing against big labs on health agents. At the same time, pushing more ML onto the device via on‑chip models reduces reliance on cloud inference, a pattern that will matter as regulators, payers and users push back on sending sensitive data to remote servers.


